Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis - Lip, G Y; Keshishian, A; Kamble, S (Thromb Haemost, 2016)
, et al.